ArticleCureus2026
Multimodal Management of Isolated Pulmonary Metastasis From Choroidal Melanoma: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Choroidal melanoma (CM) is the most common type of uveal melanoma (UM), which represents the most common primary intraocular malignancy in adults, and it is characterized by a high risk of distant metastasis despite adequate local treatment. While the liver is the predominant site of relapse, isolated pulmonary involvement can occur, which represents an uncommon clinical phenotype. We report the case of a 47-year-old woman with late isolated lung metastasis from previously treated CM, diagnosed eight years after primary treatment with episcleral brachytherapy. Comprehensive genomic profiling revealed a high tumor mutational burden (TMB) of 16.5 mutations/Mb and a somatic nonsense neurofibromin 1 (NF1) variant (p.R2637*), in the absence of B-Raf proto-oncogene, serine/threonine kinase (BRAF) mutation or neuroblastoma RAS viral oncogene homolog (NRAS) mutation, findings atypical for UM. The patient was human leukocyte antigen A02:01 (HLA-A02:01) negative, precluding tebentafusp therapy. She received dual immune checkpoint blockade (nivolumab 1 mg/kg plus ipilimumab 3 mg/kg), experiencing manageable cutaneous and endocrine toxicities. However, she subsequently experienced disease progression. Subsequent management included stereotactic body radiotherapy (SBRT) (45 Gy in five fractions) and cytotoxic chemotherapy with carboplatin area under the curve 5 (AUC 5) and paclitaxel (175 mg/m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.